MEDICAL ONCOLOGY · MEMORIAL GÖZTEPE
Doç. Dr. Atakan Demir
Associate Professor of Medical Oncology · Memorial Göztepe Hospital
Atakan Demir is a medical oncologist at Memorial Göztepe Hospital, where he has practised since 2025. He trained in internal medicine and then medical oncology at Istanbul University Cerrahpaşa Faculty of Medicine, completing his oncology specialty in 2016, and spent 2015–2016 as a post-doctoral fellow in medical oncology at the MD Anderson Cancer Center in Houston. From 2018 to 2025 he worked at Acıbadem Maslak Hospital. His clinical focus is gastrointestinal cancer — colorectal, gastric, oesophageal, pancreatic, liver and biliary tumours — and he has been a site investigator on international phase III trials published in the New England Journal of Medicine and the Journal of Clinical Oncology.
Specialties:
Oncology
48
indexed works (OpenAlex)
266
citations (OpenAlex)
9
h-index (OpenAlex)
Colorectal cancerGastric and gastro-oesophageal junction cancerPancreatic and biliary tract cancerLiver cancerOesophageal cancerImmunotherapy
A BergemHealth coordinator arranges contact with the professor within 24–48 hours on business days.
Direct contract with BergemHealth
CONSULTATION LANGUAGES
Turkish
English
French
ISTANBUL · 08/2026
EDUCATION & CAREER
Timeline
1997–2003
Medical degree, Istanbul University Cerrahpaşa Faculty of Medicine
2006–2011
Residency in internal medicine, Istanbul University Cerrahpaşa Faculty of Medicine
2012–2016
Fellowship in medical oncology, Istanbul University Cerrahpaşa Faculty of Medicine
2015–2016
Post-doctoral fellow in medical oncology, MD Anderson Cancer Center, Houston, USA
2018–2025
Medical oncologist, Acıbadem Maslak Hospital, Istanbul
2025–present
Medical oncologist, Memorial Göztepe Hospital, Istanbul
PUBLICATIONS
Scientific work
-
2025New England Journal of Medicine«Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer»
-
2025New England Journal of Medicine«Imlunestrant with or without Abemaciclib in Advanced Breast Cancer»
-
2024Journal of Clinical Oncology«Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study»
-
2023New England Journal of Medicine«First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion-Positive NSCLC»
-
2019World Journal of Surgical Oncology«Tumor budding for predicting prognosis of resected rectum cancer after neoadjuvant treatment»
CLINIC
Where they practise
Direct contract with BergemHealth at every listed clinic.
REQUEST
Tell me about your case — I’ll read it personally.
Fill in the short form on the consultation page — diagnosis, preferred timing, attached records. We assemble a tumour board for your case and reply within 4 hours.
Open the consultation form- Reply within 4 hours during business hours
- Confidentiality guaranteed
- Coordinator-translator inside the doctor’s office
- Tumour board of 2–3 professors within 72 hours
OTHER DOCTORS
Similar BergemHealth professors
Adjacent specialties and second opinions. Direct contracts, verified cases.